2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 207

Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Abstract Number: 208

Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Abstract Number: 209

Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Abstract Number: 210

Skin Events with Febuxostat in Gout Patients and Previous Skin Reactions to Allopurinol. a Retrospective Review
Abstract Number: 211

Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia
Abstract Number: 212

Pegloticase Provides Clinical Benefit in Patients with Chronic Refractory Gout Who Did Not Meet the Clinical Trial Biochemical Definition of Response
Abstract Number: 213

Prophylaxis for Infusion Reactions to Pegloticase: An Analyis of Two Different Corticosteroid Pre-Infusion Regimens in US Community Rheumatology Practices
Abstract Number: 214

Anakinra Compared to Prednisone on the Treatment of Acute CPPD Crystal Arthritis, a Randomized, Controlled, Double-Blind Study
Abstract Number: 215

Anakinra Is Effective and Well Tolerated in Medically Complex Patients Including Transplant Recipients with Gout
Abstract Number: 216

Colchicine Prescribing As a Parameter for QA/QI Process in Gout Care
Abstract Number: 217

The Effect of Regular Treatment on Disability in a Cohort of Patients with Gout.
Abstract Number: 218

Accuracy of Humasens-Plus Point-of-Care Uric Acid Meter Using Capillary Blood Obtained By Fingertip Puncture
Abstract Number: 219

Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Abstract Number: 220

Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Abstract Number: 221

Ultrasound in Gout: The Clinical Application

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].